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Mutations in CDCA7 and HELLS cause
immunodeﬁciency–centromeric instability–facial
anomalies syndrome
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Silve`re M. van der Maarel1 & Hiroyuki Sasaki2
The life-threatening Immunodeﬁciency, Centromeric Instability and Facial Anomalies (ICF)
syndrome is a genetically heterogeneous autosomal recessive disorder. Twenty percent of
patients cannot be explained by mutations in the known ICF genes DNA methyltransferase 3B
or zinc-ﬁnger and BTB domain containing 24. Here we report mutations in the cell division
cycle associated 7 and the helicase, lymphoid-speciﬁc genes in 10 unexplained ICF cases. Our
data highlight the genetic heterogeneity of ICF syndrome; however, they provide evidence that
all genes act in common or converging pathways leading to the ICF phenotype.
DOI: 10.1038/ncomms8870 OPEN
1 Department of Human Genetics, Leiden University Medical Center, Leiden 2333ZA, The Netherlands. 2 Division of Epigenomics and Development,
Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan. 3 CNRS UMR7216, Epigenetics and Cell
Fate, Universite´ Paris Diderot, Sorbonne Paris Cite´, 75205 Paris, France. 4 Division of Bioinformatics, Department of Multi-scale Research Center for Medical
Science, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan. 5 Department of Paediatric Immunology, Newcastle Upon Tyne
Hospital, NHS Foundation Trust, Newcastle Upon Tyne, UK. 6 Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne NE1 4LP, UK.
7Division of Pediatrics and Pediatric Rheumatology, G. Gaslini Scientiﬁc Institute, Genova 16147, Italy. 8 Institute of Medical Molecular Genetics, University of
Zurich, Schlieren 8952, Switzerland. 9Department of Biology, ETH Zurich, Zurich 8093, Switzerland. 10 Department of Oncology, University Children’s
Hospital, Zurich 8032, Switzerland. 11 Department of Pediatric Immunology and Allergy, Necmettin Erbakan University, Meram Medical Faculty, Konya
42080, Turkey. 12 Centre de Re´fe´rence De´ﬁcits Immunitaires He´re´ditaires, AP-HP, 75743 Paris, France. 13 Centre d’Etude des De´ﬁcits Immunitaires, Hoˆpital
Universitaire Necker-Enfants Malades, AP-HP, 75743 Paris, France. 14 Laboratoire de Ge´ne´tique Humaine des Maladies Infectieuses, Inserm, 75743, Paris,
France. 15 Universite´ Paris Descartes, Institut Imagine, Sorbonne Paris, 75743 Paris, France. 16 Unite´ d’immunologie et d’he´matologie pe´diatrique, Hoˆpital
Necker-Enfants Malades, 75743, Paris, France. 17 Inserm UMR 768, 75015 Paris, France. 18 Centre de Re´fe´rence De´ﬁcits Immunitaires He´re´ditaires, Institut
d’He´matologie et d’Oncologie Pe´diatrique, CHU de Lyon, 69008 Lyon, France. 19 Service d’he´pato-gastro-ente´rologie et nutrition, endocrinologie et
ne´phrologie pe´diatriques, Hoˆpital de la Timone, CHU Marseille, 13385 Marseille, France. 20Department of Pediatric Hematology and Oncology, Shikoku
Medical Center for Children and adults, Kagawa 765-8507, Japan. 21 Department of Pediatrics, Ooida Hospital, Kochi 788-0001, Japan. 22 Department of
Epigenetic Medicine, Faculty of Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi 409-3898,
Japan. 23 Department of Pediatrics, Laboratory for Immunology, Leiden University Medical Center, Leiden 2333ZA, The Netherlands. 24Department of
Pediatric Infectious Diseases and Immunology, Radboud University Nijmegen Medical Center, Nijmegen 6500HC, The Netherlands. w Present address:
Institutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, China (J.W.); Shanghai Institute for Pediatric Research, Xin Hua Hospital,
Shanghai Jiao Tong University School of Medicine, Shanghai, China (Y.S.). Correspondence and requests for materials should be addressed to C.F.
(email: claire.francastel@univ-paris-diderot.fr) or to S.M. (email: Maarel@lumc.nl) or to H.S. (email: hsasaki@bioreg.kyushu-u.ac.jp).
NATURE COMMUNICATIONS | 6:7870 | DOI: 10.1038/ncomms8870 |www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
I
mmunodeﬁciency, Centromeric Instability and Facial
Anomalies (ICF) syndrome is characterized by recurrent and
often fatal respiratory and gastrointestinal infections as a
consequence of hypo- or a-gammaglobulinemia in the presence
of B cells1,2. Nearly all patients also present with distinct
facial anomalies, including hypertelorism, ﬂat nasal bridge
and epicanthus1,2. Centromeric instability is the cytogenetic
hallmark of ICF syndrome. It involves the juxtacentromeric
heterochromatin repeats on chromosomes 1, 9 and 16 and is
comparable to what is observed after treatment of cells with
demethylating agents3,4. Therefore, CpG hypomethylation of
juxtacentromeric satellite types II and III is a diagnostic for ICF
syndrome, with additional hypomethylation of centromeric
a-satellite repeats in DNMT3B mutation-negative patients5,6.
Mutations in the DNA methyltransferase 3B (DNMT3B) gene
(OMIM 602900; ICF1) account for B50% of ICF cases, while
B30% of cases have mutations in the zinc-ﬁnger and BTB
domain containing 24 (ZBTB24) gene (OMIM 614064; ICF2)2,5.
DNMT3B is a de novo DNA methyltransferase, primarily acting
during early development with a preference for CpG dense
regions7. ICF1 mutations in the catalytic domain of DNMT3B
result in largely reduced methyltransferase activity8,9. The
function of ZBTB24 is unknown, but it belongs to a family of
ZBTB proteins of which many have regulatory roles in
haematopoietic differentiation10,11. Despite the successful
identiﬁcation of ICF genes, the pathophysiological mechanism
underlying the syndrome remains largely unresolved.
Previous studies indicated further genetic heterogeneity in
ICF syndrome2. To identify the genetic cause in genetically
unexplained cases (ICFX), we combined homozygosity mapping
with whole-exome sequencing. By using an autosomal recessive
inheritance model and prioritizing homozygous variants in
consanguineous families, we now identify four different
homozygous and potentially damaging variants in the cell
division cycle associated 7 (CDCA7) gene in ﬁve ICFX patients
(now referred to as ICF3). In an additional ﬁve ICFX patients, we
identify compound heterozygous and homozygous variants in the
helicase, lymphoid-speciﬁc (HELLS) gene (ICF4). We show that
knockdown of both new ICF genes leads to hypomethylation of
juxtacentromeric heterochromatin repeats in a murine cell model.
Our results emphasize the genetic heterogeneity of ICF syndrome,
nonetheless providing evidence that all four ICF genes are
involved in at least one common pathway.
Results
Missense mutations in CDCA7 cause ICF syndrome type 3. We
selected 13 ICFX patients from 11 families, negative for mutations
in DNMT3B or ZBTB24, of whom the clinicopathological char-
acteristics are listed in Supplementary Table 1. Hypomethylation
of pericentromeric satellite type II (Sat II), common to all ICF
patients, and centromeric a-satellite DNA repeats, shown to be
affected only in ICF2 and ICFX, was shown before for a subset of
patients2,5,6,12. For an additional set of ICFX patients, we
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Figure 1 | Homozygous missense mutations in CDCA7 in ﬁve ICF3 patients. (a) Schematic representation of CDCA7, with the identiﬁed homozygous
missense mutations in red. Sequence outtake: 4-CXXC-type zinc-ﬁnger domain, CXXC motifs are underlined, mutated residues in red. (b–d) Sanger
sequencing conﬁrmation of missense mutations in CDCA7 in families A–C. All variants were homozygous, the reference sequence is displayed for
comparison. (e) Sanger sequencing conﬁrmation of the homozygous missense CDCA7 mutation in patients 2.2 (proband) and 2.3 of family D. Both parents
are heterozygous for the variant, sibling 2.1 is unaffected and homozygous for the wild-type (wt) allele.
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conﬁrmed Sat II and a-satellite hypomethylation using Southern
blot analysis (Supplementary Fig. 1). In ﬁve ICFX patients from
four families we identiﬁed and conﬁrmed homozygous missense
mutations in CDCA7, all near the ﬁrst two zinc-ﬁnger motifs in
the conserved carboxyterminal 4-CXXC-type zinc-ﬁnger domain
(Fig. 1a–e). Segregation with disease was conﬁrmed in family D
and all mutations were predicted to be pathogenic and have an
allele frequency supporting pathogenicity (Fig. 1e, Supplementary
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Figure 2 | Mutations in HELLS in ﬁve ICF4 patients. (a) Schematic representation of HELLS, with the identiﬁed mutations in red. (b) Sanger sequencing
conﬁrmation of HELLS mutations in family E. Only c.370þ 2T4A was identiﬁed in maternal DNA, indicating different allelic origins of both mutations, or de
novo occurrence of the second mutation. (c) RT–PCR analysis of HELLS mRNA on treatment of patient-derived ﬁbroblasts with cycloheximide (C) revealed
that c.370þ 2T4A leads to complete skipping of exon 5 and disruption of the open reading frame. Ethanol-treated samples (E) served as controls,
alternative splicing was conﬁrmed using Sanger’s sequencing in two independent experiments for both samples. (d) Sanger sequencing conﬁrmation of a
homozygous out-of-frame deletion in HELLS in family F. Both parents as well as unaffected sibling 2.1 are heterozygous for the deletion allele; unaffected
sibling 2.3 is homozygous for the wt allele. (e) Sanger sequencing conﬁrmation of a homozygous in-frame deletion in HELLS in family G. Both parents are
heterozygous for the deletion allele. (f) Sanger sequencing conﬁrmation of nonsense mutations in HELLS in family H. Different allelic origin was conﬁrmed
in parental DNA. (g) Southern blot analysis of minor satellite DNA methylation in Dnmt3b / and siRNA-treated wt MEFs after digesting DNA with MspI
or its methylation-sensitive isoschizomer HpaII revealed CpG hypomethylation on knockdown of Zbtb24, Cdca7 and Hells. Molecular weights of the 2-Log
DNA size marker are in kilobasepairs.
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Table 1). CDCA7 is involved in neoplastic transformation,
MYC-dependent apoptosis and haematopoietic stem cell
emergence; however, its molecular function is unknown13,14.
All four zinc-ﬁnger motifs are completely conserved in the highly
homologous 4-CXXC zinc-ﬁnger domain of the transcriptional
repressor CDCA7-Like (CDCA7L; Supplementary Fig. 2). The
repressive activity of CDCA7L is dependent on its 4-CXXC
domain, and by homology CDCA7 mutations in ICF3 may
disrupt a similar function15.
Mutations in HELLS cause ICF syndrome type 4. In an
additional ﬁve ICFX patients from four families, we identiﬁed
mutations in HELLS that were predicted to be pathogenic and
with allele frequencies supporting pathogenicity (Fig. 2a,
Supplementary Table 1, ICF4). In affected members of family E,
we identiﬁed a missense mutation in the conserved helicase
domain (c.2096A4G;p.[Gln699Arg]) and an intronic mutation
leading to destruction of the splice donor site in intron 5
(c.370þ 2T4A; Fig. 2b). Different allelic origin is supported by
analysis of maternal DNA, which carried only the splice site
mutation (Fig. 2c). To analyse the effect of the lost splice donor
site on mRNA processing, ﬁbroblasts of both patients were
treated with cycloheximide to inhibit nonsense-mediated decay.
Upon treatment, reverse transcriptase–PCR (RT–PCR) analysis
showed increased levels of a splice variant with complete skipping
of exon 5, leading to a frameshift followed by a premature stop
codon in exon 6 (Fig. 2c).
The patient in family F carries a homozygous out-of-frame
deletion (c.2283_2286delGTCT;p.[Ser762Argfs*4]), resulting in a
frameshift and introduction of a premature stop codon in exon
20. The unaffected siblings 2.1 and 2.3 were found to be
heterozygous for the deletion or homozygous for the wild-type
allele, respectively (Fig. 2d). In family G we found a deleterious
homozygous in-frame deletion in the C-terminal domain
of HELLS, leading to the deletion of Leucine 801
(c.2400_2402delGTT;p.[Leu801del]; Fig. 2e). The proband of
family H carries a nonsense mutation (c.610A4T;p.[Lys204*])
and a duplication causing the insertion of a stop codon
(c.374_381dup;p.[Lys128*]), suggesting that absence of HELLS
is compatible with human life, whereas Hells / mice die
perinatally16. Different allelic origin of the mutations was
conﬁrmed in parental DNA (Fig. 2f).
ICF genes converge at centromeric DNA methylation regulation.
In mouse, HELLS is required for T-cell proliferation and mediates
de novo DNA methylation, through its interaction with
DNMT3B, dependent on its ATPase domain16–19. Genome-wide
loss of CpG methylation, including centromeric repeats, has been
observed in Hells / mice, reminiscent of what has been
described in Dnmt3b knockout mice and in mouse models for
ICF1 (refs 20,21). We show that transient depletion of HELLS,
CDCA7 and ZBTB24, but not DNMT3B, resulted in decreased
CpG methylation at centromeric repeats in wild-type mouse
embryonic ﬁbroblasts (MEFs, Fig. 2g, Supplementary Fig 3a,b).
This conﬁrms that DNMT3B acts during establishment of
centromeric CpG methylation22. Moreover, it supports a role
for ZBTB24 and CDCA7 in maintenance of CpG methylation at
centromeric repeats, and, combined with previously published
work, suggests that HELLS may be involved in both processes19.
By identifying two new ICF syndrome genes this study
highlights the genetic heterogeneity of the syndrome. The
identiﬁcation of at least one additional disease gene is expected
with still a few cases remaining genetically unresolved. The
complex, but highly overlapping, pathophysiology suggests that
all ICF genes act in common or converging pathways involved in
immunity, chromatin regulation and development. Convergence
is supported by hypomethylation of pericentromeric repeats,
which is common to all ICF subgroups, however the result of
different defective pathways in the establishment and/or main-
tenance of CpG methylation.
Methods
Patients. All samples were obtained in an anonymized manner, and all families
gave consent for genetic analyses. The study was approved by the Medical Ethical
Committee of the Leiden University Medical Center, the local ethics committee of
Necker-Enfants Malades Hospital, Paris, France and the Kyushu University
Institutional Review Board for Human Genome/Gene Research. The patient from
family A (referred to as patient 2 in ref. 23), patients from families B and C
(referred to as pC and pS, respectively, in ref. 12), patient 2.2 from family D and the
patients in family E (referred to as P4 and P8/P9 in ref. 5), as well as the three
remaining ICFX cases (referred to as pN and P1 in ref. 12 and P4 in ref. 24)
all show typical clinical features of ICF syndrome including hypo- or
agammaglobulinemia in the presence of B cells, combined with the classical
cytogenetic abnormalities involving chromosomes 1, 9 and 16, and
hypomethylation of a-satellite DNA in addition to Sat II hypomethylation. The
critical features of all patients are summarized in Supplementary Table 1; further
details can be found in previous descriptions of these patients2,5,6,12,23,24.
Gene identiﬁcation by homozygosity mapping and sequencing. Homozygosity
mapping was performed using the Sentrix HumanHap-300 Genotyping BeadChips
(Illumina). To this end, 750-ng genomic DNA was processed with the Inﬁnium II
Whole-Genome Genotyping Assay (Illumina). After DNA ampliﬁcation, frag-
mentation, precipitation and resuspension, DNA was applied to the BeadChip and
incubated overnight, followed by enzymatic base extension, ﬂuorescent staining of
the beads and detection of ﬂuorescent intensities using the BeadArray Reader
(Illumina). To identify regions of homozygosity, B allele frequencies were assessed
for all single-nucleotide polymorphisms using BeadStudio version 3.2 (Illumina).
For a subset of patients, whole-exome sequencing was performed in the Neuromics
project by deCODE Genetics (Reykjavik—Iceland) and analysed using deCODE
Clinical Sequence Miner. Recessive analysis for multiple cases and controls and
gene variant effect count (with variant effect predictor consequences moderate to
high) were used to identify possible recessive mutations. For an additional set of
patients, DNA libraries for whole-exome sequencing were constructed using the
SureSelect Human All Exon V5 kit (Agilent Technologies) according to the
manufacturer’s instructions. Sequencing was performed on the Illumina HiSeq2500
platform to generate 100 bp paired-end reads. Reads were mapped to the
reference human genome (UCSC hg19) with the Burrows-Wheeler Alignment
tool (BWA v0.7.4)25. Duplicate reads were removed by Picard (v1.87). We called
SNVs and indels using the Genome Analysis Toolkit (GATK v2.5-2)26.
Annotations of variants were made using Annotate Variation (ANNOVAR)27.
For conﬁrmation, relevant exons and ﬂanking sequences of CDCA7 and HELLS
were ampliﬁed using standard PCR; products were puriﬁed and analysed using
Sanger sequencing. Sequence tracks were analysed and visualized using
ContigExpress (Vector NTI, Invitrogen-Life Technologies). PCR primers are
listed in Supplementary Table 2.
Cycloheximide treatment and RT–PCR analysis. Early-passage (Po6) patient-
derived primary ﬁbroblasts were maintained in DMEM F12 (31331) supplemented
with 20% heat-inactivated fetal calf serum, 1% penicillin–streptomycin, 1% sodium
pyruvate and 1% HEPES (all Invitrogen-Life Technologies). Cells were treated with
250 mgml 1 cycloheximide (dissolved in ethanol, 01810, Sigma-Aldrich) for 4 h
using equal volumes of ethanol as control. After treatment, cells were harvested in
Qiazol lysis reagent and RNA was isolated using the miRNeasy mini kit (both
Qiagen) all according to the manufacturer’s instructions. Total RNA (2 mg) was
used for random primed cDNA synthesis using the RevertAid ﬁrst-strand cDNA
synthesis kit (Thermo Scientiﬁc). Transcripts were ampliﬁed using standard
PCR with primers listed in Supplementary Table 2, separated by standard gel
electrophoresis and sequenced by Sanger’s sequencing.
Knockdown of gene expression in MEFs. The use of animal work has been
reviewed by the Animal Experimentation Ethical Committee Buffon (CEEA-40),
Paris, France, and was approved under the number CEB-06-2012. Female C57BL/
6N pregnant mice, aged 3–6 months, were killed at 12.5 days post conception, and
individual MEF clones were isolated from each embryo of the litter. Primary MEFs
were cultivated for no more than two to three passages in complete media (DMEM
glutamax supplemented with 10% fetal bovine serum, 100Uml 1 penicillin,
100 mgml 1 streptomycin, all from Life Technologies). Two rounds of transfection
with synthetic short interfering RNAs (siRNAs) at a ﬁnal concentration of 20 nM
were performed using Interferin transfection reagent (Polyplus transfection) fol-
lowing the manufacturer’s instructions: a ﬁrst round on MEFs in suspension and
the second when cells were allowed to adhere to the plate. Cells were collected after
48 h for genomic DNA extraction. Sequences of siRNAs used in the study are listed
in Supplementary Table 2.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8870
4 NATURE COMMUNICATIONS | 6:7870 | DOI: 10.1038/ncomms8870 |www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Satellite DNA methylation analysis using Southern blot analysis. Satellite II
and a-satellite methylation in whole-blood DNA was analysed using Southern blot
analysis of 2 mg genomic DNA digested with methylation-sensitive restriction
enzymes HhaI for analysis of Sat-a or BstBI for analysis of Satellite II repeats. Both
enzymes were purchased from Fermentas. After overnight digestion, DNA was
separated by electrophoresis using 0.8% agarose gels. DNA was transferred
overnight to Hybond-Nþ membranes (GE Healthcare) and hybridized with a
radioactive probe recognizing the a-satellite and satellite II repeats, respectively.
Signals were detected by phosphoimaging or by exposure to X-ray ﬁlms. For
analysis of murine satellite repeats, genomic DNA was extracted and puriﬁed from
MEFs using the NucleoSpin Tissue kit (Macherey-Nagel) according to the man-
ufacturer’s instructions. The DNA pellet was eluted in Tris EDTA buffer con-
taining 20 mgml 1 RNAse A. Genomic DNA from MEFs (500 ng) was digested
with 20 units of MspI or HpaII (New England Biolabs) for 16 h to analyse the DNA
methylation patterns of centromeric minor satellite repeats. The digested DNA
fragments were separated by electrophoresis using 1% agarose gels and transferred
overnight to Hybond-Nþ membranes (GE Healthcare) in 20 SSC. After
ultraviolet crosslink, the membranes were pre-hybridized in 6 SSC, 5 Den-
hardt and 0.1% SDS and then hybridized with 32P-labelled minor satellite oligo-
nucleotide probe: (50-ACATTCGTTGGAAACGGGATTTGTAGAACAGTG
TATATCAATGAGTTACAATGAGAAACAT-30).
Pre-hybridization and hybridization were carried out at 42 C for 1 h. The
membranes were washed three times in 6 SSC and 0.1% SDS at 37 C and signals
were detected by phosphorimaging using FLA 7000 phosphorimager (Fuji).
Uncropped scans of the Southern blots are presented in Supplementary Figs 4
and 5.
Quantiﬁcation of knockdown efﬁciency using qRT–PCR. Total RNA from
MEFs was isolated using TRIzol Reagent (Life Technologies) according to the
manufacturer’s instructions. Contaminant genomic DNA was eliminated with
TURBO DNA-free kit (Ambion). Reverse transcription was carried out using 1 mg
DNA-free RNA and 50mM random hexamers, 20U of RNase Out and 100U
of RevertAid reverse transcriptase (Life Technologies). Complementary DNA
reactions were used as templates for PCR reactions. Real-time PCR was performed
using the light cycler-DNA MasterPLUS SYBR Green I mix (Thermo Scientiﬁc)
supplemented with 0.5 mM of speciﬁc primer pairs (listed in Supplementary
Table 2). Real-time qPCRs were run on a light cycler rapid thermal system (Light
Cycler 480 2.0 Real time PCR system, Roche) with 20 s of denaturation at 95 C,
20 s of annealing at 60 C and 20 s of extension at 72 C for all primers, and
analysed by the comparative CT (nCt) method.
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